Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 570-578

  Boursier, Jérôme ^a,b   Vergniol, Julien ^c   Guillet, Anne ^a   Hiriart, Jean Baptiste ^c   Lannes, Adrien ^a   Le Bail, Brigitte ^d   Michalak, Sophie ^a   Chermak, Faiza ^c   Bertrais, Sandrine ^b   Foucher, Juliette ^c   Oberti, Frédéric ^a,b   Charbonnier, Maude ^c   Fouchard Hubert, Isabelle ^a,b   Rousselet, Marie Christine ^a,b   Calès, Paul ^a,b   de Lédinghen, Victor ^c,e  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b LUNAM University   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Blood fibrosis test; Liver stiffness; NAFLD

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; BILIRUBIN BLOOD LEVEL; CLINICAL PRACTICE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELASTOGRAPH; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPASCORE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST KIT; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; SENSITIVITY AND SPECIFICITY; TRANSIENT ELASTOGRAPHY; BIOPSY; LIVER CIRRHOSIS; LONGITUDINAL STUDY;

BIOMARKERS; BIOPSY; CROSS-SECTIONAL STUDIES; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

EID: 84979656488     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.04.023     Document Type: Article

References (45)

1. [1] Younossi, Z.M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9 (2011), 524–530.
2. [2] Das, K., Mukherjee, P.S., Ghosh, A., Ghosh, S., Mridha, A.R., Dhibar, T., et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51 (2010), 1593–1602.
3. [3] Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
4. [4] Brunt, E.M., Kleiner, D.E., Wilson, L.A., Belt, P., Neuschwander-Tetri, B.A., Network, N.C.R., Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53 (2011), 810–820.
5. [5] Brunt, E.M., Kleiner, D.E., Wilson, L.A., Unalp, A., Behling, C.E., Lavine, J.E., et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 49 (2009), 809–820.
6. [6] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 149, 2015, e310.
7. [7] Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
8. [8] Younossi, Z.M., Stepanova, M., Rafiq, N., Makhlouf, H., Younoszai, Z., Agrawal, R., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53 (2011), 1874–1882.
9. [9] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
10. [10] Bravo, A.A., Sheth, S.G., Chopra, S., Liver biopsy. N Engl J Med 344 (2001), 495–500.
11. [11] Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654 e641–e649; quiz e639–e640.
12. [12] Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
13. [13] Musso, G., Gambino, R., Cassader, M., Pagano, G., Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43 (2011), 617–649.
14. [14] Boursier, J., Rousselet, M.C., Aube, C., Cales, P., Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opin Med Diagn 6 (2012), 381–394.
15. [15] Degos, F., Perez, P., Roche, B., Mahmoudi, A., Asselineau, J., Voitot, H., et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 53 (2010), 1013–1021.
16. [16] Zarski, J.P., Sturm, N., Guechot, J., Paris, A., Zafrani, E.S., Asselah, T., et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study. J Hepatol 56 (2012), 55–62.
17. [17] European Association for Study of the Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63 (2015), 237–264.
18. [18] Angulo, P., Bugianesi, E., Bjornsson, E.S., Charatcharoenwitthaya, P., Mills, P.R., Barrera, F., et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 145, 2013, e784.
19. [19] Kim, D., Kim, W.R., Kim, H.J., Therneau, T.M., Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
20. [20] Harrison, S.A., Oliver, D., Arnold, H.L., Gogia, S., Neuschwander-Tetri, B.A., Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57 (2008), 1441–1447.
21. [21] Cales, P., Laine, F., Boursier, J., Deugnier, Y., Moal, V., Oberti, F., et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 50 (2009), 165–173.
22. [22] Wai, C.T., Greenson, J.K., Fontana, R.J., Kalbfleisch, J.D., Marrero, J.A., Conjeevaram, H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003), 518–526.
23. [23] Sterling, R.K., Lissen, E., Clumeck, N., Sola, R., Correa, M.C., Montaner, J., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43 (2006), 1317–1325.
24. [24] Imbert-Bismut, F., Ratziu, V., Pieroni, L., Charlotte, F., Benhamou, Y., Poynard, T., Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001), 1069–1075.
25. [25] Adams, L.A., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51 (2005), 1867–1873.
26. [26] Calès, P., Oberti, F., Michalak, S., Hubert-Fouchard, I., Rousselet, M.C., Konate, A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42 (2005), 1373–1381.
27. [27] Cales, P., Veillon, P., Konate, A., Mathieu, E., Ternisien, C., Chevailler, A., et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 41 (2008), 10–18.
28. [28] Castera, L., Forns, X., Alberti, A., Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48 (2008), 835–847.
29. [29] Boursier, J., Zarski, J.P., de Ledinghen, V., Rousselet, M.C., Sturm, N., Lebail, B., et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 57 (2013), 1182–1191.
30. [30] Schwabl, P., Bota, S., Salzl, P., Mandorfer, M., Payer, B.A., Ferlitsch, A., et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int 35 (2015), 381–390.
31. [31] Lambert, J., Halfon, P., Penaranda, G., Bedossa, P., Cacoub, P., Carrat, F., How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 54 (2008), 1372–1378.
32. [32] Boursier, J., Brochard, C., Bertrais, S., Michalak, S., Gallois, Y., Fouchard-Hubert, I., et al. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther 40 (2014), 178–188.
33. [33] Boursier, J., de Ledinghen, V., Poynard, T., Guechot, J., Carrat, F., Leroy, V., et al. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. J Hepatol 62 (2015), 807–815.
34. [34] Boursier, J., Bertrais, S., Oberti, F., Gallois, Y., Fouchard-Hubert, I., Rousselet, M.C., et al. Comparison of accuracy of fibrosis degree classifications by liver biospy and non invasive tests in chronic hepatitis C. BMC Gastroenterol, 30, 2011, 132.
35. [35] Boursier, J., de Ledinghen, V., Zarski, J.P., Fouchard-Hubert, I., Gallois, Y., Oberti, F., et al. Comparison of 8 diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely non-invasive. Hepatology 55 (2012), 58–67.
36. [36] Poynard, T., Imbert-Bismut, F., Munteanu, M., Messous, D., Myers, R.P., Thabut, D., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol, 3, 2004, 8.
37. [37] de Ledinghen, V., Wong, V.W., Vergniol, J., Wong, G.L., Foucher, J., Chu, S.H., et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol 56 (2012), 833–839.
38. [38] Myers, R.P., Pomier-Layrargues, G., Kirsch, R., Pollett, A., Duarte-Rojo, A., Wong, D., et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012 (2012), 199–208.
39. [39] Wong, V.W., Vergniol, J., Wong, G.L., Foucher, J., Chan, A.W., Chermak, F., et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 107 (2012), 1862–1871.
40. [40] Afdhal, N.H., Nunes, D., Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99 (2004), 1160–1174.
41. [41] Guha, I.N., Parkes, J., Roderick, P.R., Harris, S., Rosenberg, W.M., Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 55 (2006), 1650–1660.
42. [42] Sebastiani, G., Alshaalan, R., Wong, P., Rubino, M., Salman, A., Metrakos, P., et al. Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis. PLoS One, 10, 2015, e0128774.
43. [43] Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10 (2013), 330–344.
44. [44] Armstrong, M.J., Adams, L.A., Canbay, A., Syn, W.K., Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59 (2014), 1174–1197.
45. [45] Lade, A., Noon, L.A., Friedman, S.L., Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 26 (2014), 100–107.